DR. KIPLANGAT SIGEI
Dr. Sigei is a medical doctor with over 10 years work experience in clinical medicine, clinical research and pharmaceutical and in-vitro diagnostics medical affairs. Since June 2019, he is serving as the Medical Affairs Manager for Anglophone Africa at BioMérieux, a French in vitro diagnostic company, where he is responsible for leading the scientific and medical engagement of BioMérieux clinical diagnostic portfolio in English speaking countries of East, West and Southern Africa.
After working as a doctor in clinical practice and clinical research, Dr. Sigei began his career in medical affairs by joining Novartis Pharmaceutical Services in 2013 as Medical Science Liaison for East Africa where I took on the role of scientifically engaging regional stakeholders, gathering medical insights in key therapeutic areas and supporting product strategy by carrying out key educational and capacity building activities. He was later promoted to the position of Medical Advisor, a more strategic role leading medical affairs strategy and later to Head of Medical Affairs for East Africa & Head of Medical Operations for Sub-Sahara Africa a senior leadership position with overall responsibility for Medical Affairs strategy and operations, Medical talent development, building medical capabilities and driving pre-launch strategy. In this time he was recognized with various accolades including the Business Daily Kenya Top 40 Men Under 40 2017.
Dr. Sigei holds a Bachelor of Medicine & Bachelor of Surgery Degree from University of Nairobi as well as Master of Science in Public Health (London) and 2 Post-graduate Diplomas in Tropical Medicine & Hygiene (EADTMH – London) and Global Health – Non-Communicable Diseases (Edinburgh). His passion is in collaborating to provide solutions to health technology utilization and access with focus on clinical research, medical education, scientific engagement, patient access and mentoring.
Shuhei Fujita
Shuhei Fujita, MD, PhD is the VP and Therapeutic Area head of Medical Affairs Japan in Astellas.
In this role, Dr. Fujita provides leadership for the Medical Affairs organization and leads the MA strategy for all product in Japan.
Dr. Fujita joined Astellas in 2017 as a Global Medical Lead at Development and moved to Medical Affairs from 2019.
While at Development, he successfully led and executed the clinical development and global medical programs in both of oncology and non-oncology therapeutic area.
Prior to joining Astellas, Dr. Fujita held the position of physician scientist and conducted the translational science program through the collaboration with pharmaceutical companies at National Cancer Center in Japan.
Dr. Fujita received his bachelor degree of science from the University of Tokyo, Japan.
He went on to receive his medical degree from Tokyo Medical and Dental University, Japan.
After the clinical experiences at surgery and oncology fields, Dr Fujita competed the PhD program at the same medical school.
Charlotte Kremer
Charlotte M. E. Kremer, MD, MBA is formerly the Executive VP and Head of Medical Affairs for Astellas, recently retired. In this role, Dr. Kremer provided leadership for the Medical Affairs organization globally.
Dr. Kremer joined Astellas in 2012 with 20 years of experience in the pharmaceutical industry. Prior to Astellas, she held the position of Vice President, Therapeutic Area Head for Ophthalmology, PVD, Rare Diseases and Neuroscience at Pfizer. While at Pfizer, she successfully led and executed the clinical development and global medical programs in these respective areas. Prior to joining Pfizer, Dr. Kremer held positions of increasing responsibility providing medical support, developing Phase 3b/4 clinical trials, and initiating and directing a Medical Liaison program at Organon Pharmaceuticals, both in the Netherlands and in the United States. A native of the Netherlands, Dr. Kremer received her medical degree from the University of Utrecht, The Netherlands. She went on to receive her Diploma Pharmaceutical Medicine (DPM) from Universite Libre de Bruxelles. After transferring to the United States, Dr. Kremer completed the Executive MBA program at New York University’s Leonard N. Stern School of Business.
